January 20, 2021: “Merck, known as MSD outside the United States and Canada, today announced that the U.S. FDA has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.
The approval of VERQUVO by the FDA, which is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics, is based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority regulatory review.
VERQUVO (vericiguat) 2.5 mg, 5 mg, and 10 mg tablets is being jointly developed with Bayer AG.
The VERQUVO label contains a boxed warning that indicates that VERQUVO should not be administered to pregnant females because it may cause fetal harm. For more information, see “Selected Safety Information” below.
“Patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient IV diuretic treatment or hospitalization.
By some estimates, more than half of these patients are rehospitalized within a month of discharge due to a worsening event and approximately one in five die within two years,” said Dr. Paul W. Armstrong, cardiologist and Distinguished University Professor of Medicine at the Canadian VIGOUR Centre, University of Alberta, and study chair of the VICTORIA trial.
“The approval of VERQUVO provides doctors, health care professionals, and patients with a welcome new option to current available therapies.”
In VICTORIA, the primary efficacy objective was to determine whether VERQUVO is superior to placebo, both in combination with other heart failure therapies, in reducing the risk of cardiovascular death or heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction less than 45% following a worsening heart failure event.
VERQUVO met the primary efficacy objective based on a time-to-event analysis (hazard ratio [HR]: 0.90, 95% confidence interval [CI], 0.82-0.98; p=0.019).
Over the course of the study, there was a 4.2% reduction in annualized absolute risk with VERQUVO compared with placebo.
Therefore, 24 patients would need to be treated over an average of one year to prevent one primary endpoint event.
“VERQUVO has been shown to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics.
We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.
“This approval builds upon Merck’s proud history of developing therapies for the treatment of patients with cardiovascular disease.”
Data Supporting the Approval
The approval of VERQUVO was based on data from VICTORIA (NCT02861534), a randomized, parallel-group, placebo-controlled, double-blind, event-driven, multi-center clinical trial comparing VERQUVO to placebo in 5,050 adult patients with symptomatic chronic heart failure (New York Heart Association [NYHA] class II-IV) and left ventricular ejection fraction (LVEF) less than 45%, following a worsening heart failure event.
A worsening heart failure event was defined as heart failure hospitalization within six months or less prior to randomization or use of outpatient IV diuretics for heart failure within three months or less prior to randomization.
In VICTORIA, the primary endpoint was a composite of time to first event of cardiovascular death or hospitalization for heart failure. The median follow-up for the primary endpoint was 11 months.
VERQUVO was superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization based on a time-to-event analysis.
Patients received up to the target maintenance dose of VERQUVO 10 mg once daily or matching placebo.
Therapy was initiated at VERQUVO 2.5 mg once daily and increased in approximately two-week intervals to 5 mg once daily and then 10 mg once daily, as tolerated. Placebo doses were similarly adjusted.
After approximately one year, 90% of patients in both the VERQUVO and placebo arms were treated with the 10 mg target maintenance dose.
Study participants were: 76% male, 64% Caucasian, 22% Asian, and 5% Black. The mean age was 67 years. At randomization, 59% of patients were NYHA Class II, 40% were NYHA Class III and 1% were NYHA Class IV.
The mean LVEF was 29%. Approximately half of all patients had an EF less than 30%, and 14% of patients had an EF between 40% and 45%.
Sixty-seven percent of the patients in VICTORIA were enrolled within three months of a heart failure hospitalization index event; 17% were enrolled within three to six months of heart failure hospitalization, and 16% were enrolled within three months of outpatient treatment with IV diuretics for worsening heart failure.
The median NT-pro B-type natriuretic peptide (NT-proBNP) level was 2800 pg/mL at randomization.
Study participants were on standard of care. At baseline, 93% of patients were receiving a beta-blocker, 73% were receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), 70% were receiving a mineralocorticoid receptor antagonist (MRA), 15% were receiving a combination of an angiotensin receptor and neprilysin inhibitor (ARNI), 28% had an implantable cardiac defibrillator and 15% had a biventricular pacemaker.
Ninety-one percent of patients were treated with two or more heart failure medications (beta blocker, any renin-angiotensin system [RAS] inhibitor or MRA) and 60% of patients were treated with all three.
At baseline, 6% of patients were receiving ivabradine and 3% a sodium glucose co-transporter 2 (SGLT2) inhibitor.
In the VICTORIA trial, VERQUVO demonstrated an adverse event profile similar to placebo.
The adverse drug reactions occurring more commonly with VERQUVO than placebo and in greater than or equal to 5% of patients treated with VERQUVO in VICTORIA were hypotension (16% vs 15%) and anemia (10% vs 7%).
The VICTORIA trial included a total of 2,519 patients treated with VERQUVO (up to 10 mg once daily).
The mean duration of VERQUVO exposure was one year, and the maximum duration was 2.6 years.
VERQUVO® (vericiguat) tablets for once daily oral use (2.5 mg, 5 mg and 10 mg)
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway.
When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling.
Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction.
By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of intracellular cGMP, leading to smooth muscle relaxation and vasodilation.”
https://www.merck.com/news/merck-announces-u-s-fda-approval-of-verquvo-vericiguat/
